Alzheimer’s Disease, Oligomers, and Inflammation

The production of soluble amyloid-␤ oligomers (A␤Os) and the activation of inflammation are two important early steps in the pathogenesis of Alzheimer's disease (AD).The central role of oligomers as responsible for the neuronal dysfunction associated with the clinical features has been extended to the other protein misfolding disorders definable, on this basis, as oligomeropathies.In AD, recent evidence indicates that the mechanism of inflammation as a consequence of neurodegeneration must be assessed in favor of a more direct role of glial activation in the alteration of synaptic function.Our own experimental models demonstrate the efficacy of anti-inflammatory treatments in preventing the cognitive deficits induced acutely by A␤Os applied directly in the brain.Moreover, some promising clinical tools are based on immunological activation reducing the presence of cerebral A␤ deposits.However, the strategies based on the control of inflammatory factors as well as the amyloid aggregation show poor or non-therapeutic efficacy.Numerous studies have examined inflammatory factors in biological fluids as possible markers of the neuroinflammation in AD.In some cases, altered levels of cytokines or other inflammatory markers in cerebrospinal fluid correlate with the severity of the disease.Here we propose, according to the precision medicine principles, innovative therapeutic approaches to AD based on the patient's inflammatory profile/state.The earlier intervention and a multifactor approach are two other elements considered essential to improve the chances of effective therapy in AD.